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Abstract: (1) Background: Andrographolide (AG) is a natural compound effective for the treatment
of inflammation-mediated neurodegenerative disorders. The aim of this investigation was
the preparation of liposomes to enhance the penetration into the brain of AG, by modifying
the surface of the liposomes by adding Tween 80 (LPs-AG) alone or in combination with
Didecyldimethylammonium bromide (DDAB) (CLPs-AG). (2) Methods: LPs-AG and CLPs-AG were
physically and chemically characterized. The ability of liposomes to increase the permeability of AG
was evaluated by artificial membranes (PAMPA) and hCMEC/D3 cells. (3) Results: Based on obtained
results in terms of size, homogeneity, ⇣-potential and EE%. both liposomes are suitable for parenteral
administration. The systems showed excellent stability during a month of storage as suspensions
or freeze-dried products. Glucose resulted the best cryoprotectant agent. PAMPA and hCMEC/D3
transport studies revealed that LPs-AG and CLPs-AG increased the permeability of AG, about an
order of magnitude, compared to free AG without alterations in cell viability. The caveolae-mediated
endocytosis resulted the main mechanism of up-take for both formulations. The presence of positive
charge increased the cellular internalization of nanoparticles. (4) Conclusions: This study shows that
developed liposomes might be ideal candidates for brain delivery of AG.
Keywords: liposomes; brain delivery; surfactant; cationic liposomes; andrographolide; PAMPA;
hCMEC/D3 cells
1. Introduction
The major hindrance in the treatment of brain disorders is the blood–brain barrier (BBB),
which prevents the transfer of most drugs, peptides and large molecules across the endothelial
cell lining to protect the brain from undesirable side effects. To overcome such problems various
approaches are used.
The liposomes offer a promising tool to resolve the low permeability and high selectivity of
the BBB.
Liposomes are non-toxic, biocompatible and biodegradable drug carrier systems. Their structure
which is composed of phospholipids with an aqueous reservoir allows the encapsulation of a wide
variety of hydrophilic and hydrophobic agents [1–4]. Their phospholipid bilayer structure, similar to
physiological membranes, makes them more compatible with the lipoid layer of BBB and increase the
permeability of the drug.
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Liposomes allow relatively higher intracellular uptake than other particulate systems, due to their
sub-cellular size. They are highly studied for the treatment of central nervous system’s pathologies
such as infections, cerebral ischemia, brain tumors and neurodegenerative diseases, for instance
Parkinson’s and Alzheimer’s [5,6]. Several studies have reported an increased transport across the
BBB of encapsulated drugs both through intracerebral and intravenous administration [7].
The surface can be modified with functional ligands to enhance the brain targeting.
The functionalized nanoparticles with structures able to interact with targets on the surface of the BBB
represents a tool of enormous potentiality to ameliorate the bioavailability and to reduce side effects.
Several studies on animal models of Alzheimer’s disease demonstrated the efficacy of functionalized
liposomes to cross BBB and ameliorate impaired cognitions [8–10].
In a previous research studies, the authors developed solid lipid nanoparticles [11] and polymeric
nanoparticles [12] to deliver the andrographolide (AG), a natural compound, through the central
nervous system and ameliorate its biopharmaceutical characteristics.
AG is one of the characteristic diterpenoids from Andrographis paniculata with a wide spectrum of
biological activities, being anti-inflammatory, anticancer, hepatoprotective and antihyperlipidemic.
AG is involved in oxidative stress-related pathways implicated in stroke pathogenesis and it
protects against ischemic stroke [13]. Furthermore, it has shown protection against damage induced
by amyloid-  oligomers in vitro, it reduces amyloid-  levels and tau phosphorylation in mice,
it modulates the formation of amyloid plaques and it retrieves spatial memory functions in Alzheimer’s
disease transgenic mouse model [14]. The high lipid solubility of AG would permit its penetration of
the BBB but its poor water solubility and stability reduces its bioavailability: indeed, these factors are
the greatest drawbacks for clinical application [15,16].
In recent years, surfactants such as Tween 80 have been studied for the application in liposomal
formulations. The sterically stabilized liposomes exhibited a superior entrapment stability compared
with surfactant-free liposomes [17]. The surfactant during preparation of liposomes helps in efficient
emulsification resulting in decreasing the size of vesicles and promotes the flexibility of the vesicle to
penetrate the biological cell membranes. Tween 80 was also able to enhance liposomes half-life [18] and,
in addition, has interesting properties including the formation of a superficial coating on liposomes
that can produce “stealth” nanocarriers. Tween 80 can adsorb ApoE, which subsequently binds to its
specific LDL receptor by increasing carrier endocytosis at the level of cerebral endothelial cells [4,19–22].
Finally, this surfactant is also an inhibitor of the P-gp effluent pump [23].
Another approach is the use of the cationic liposomes, able to cross the BBB via
absorption-mediated transcytosis [24]. Several studies have shown that these cationic nanocarriers are
more efficient vehicles for drug delivery to the brain than conventional, neutral, or anionic liposomes,
possibly due to the electrostatic interactions between the cationic liposomes and the negatively charged
cell membranes, enhancing nanoparticle uptake. In particular, this kind of liposome interacts with the
endothelial cells of microvessels rich in lecithin, which binds positively charged material and induces
its cell internalization process through endocytosis [6,24]. Furthermore, the cationic liposomes very
easily fuse with cells.
The aim of the present study was the formulation of nano-sized liposomes of AG for brain
targeting. Tween 80 alone or in combination with Didecyldimethylammonium bromide (DDAB) were
considered to investigate the effects, on chemical and physical aspects, stability, release characteristics,
in vitro uptake and permeability of the AG liposomes and to ameliorate the loading and the solubility
of AG.
Liposomes were evaluated for various formulation parameters (size, polydispersity, ⇣-potential,
morphology, chemical and physical stability, in vitro release) and the optimized formulations were
studied and characterized with in vitro tests. The ability of liposomes to increase the permeability of
AG was evaluated by a Parallel Artificial Membrane Permeability Assay (PAMPA) [25]. Furthermore,
the uptake of liposomes as well as their permeability across hCMEC/D3 monolayer cells, as an in vitro
BBB model [11,26,27], were considered. Cell viability and cytotoxicity studies were also conducted.
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2. Materials and Methods
2.1. Materials
Egg phosphatidylcholine (Phospholipon 90G) was purchased from Lipoid AG, Cologne, Germany
with the support of its Italian agent AVG srl, Milan, Italy. Andrographolide, Cholesterol  95%,
Didecyldimethylammonium bromide (DDAB, 98%), Coumarin-6 (6C), Fluorescein sodium salt (NaF),
Human Serum Albumin (HSA), Phosphate Buffered Saline (PBS 0.01 M) powder (29 mM NaCl,
2.5 mM KCl, 7.4 mM Na2HPO4·7H2O, 1.3 mM KH2PO4) pH 7.4 and Tween 80 were from Sigma
Aldrich, Milan, Italy. Glucose anhydrous and sucrose came from Merck, Darmstadt, Germany.
96-well Multi-Screen PAMPA filter plate (pore size 0.45 µm) were purchased from Millipore
Corporation, Tullagreen, Carrigtwohill, County Cork, Ireland. Porcine polar brain lipid was obtained
fromAvanti Polar Lipids, Inc., Alabaster, AL, USA. All the solvents used (acetonitrile, dichloromethane,
dodecane, ethanol, formic acid, methanol) were HPLC grade from Sigma Aldrich, Milan, Italy.
Water was purified by Millipore, Milford, MA, USA, Milli-Qplus system. Phosphotungstic acid
(PTA) was from Electron Microscopy Sciences, Hatfield, PA, USA.
2.2. Preparation of Liposomal Carriers
Stealth liposomes containing Tween 80 (LPs) and cationic liposomes (CLPs) with Tween 80 and
DDAB were prepared according to the thin layer evaporation method [28]. For LPs, 160 mg of egg
phosphatidylcholine (P90G) and 10 mg of cholesterol (CHOL) were dissolved in dichloromethane.
The organic solvent was vacuum evaporated, and the dry lipid film was hydrated by adding 10 mL
PBS containing Tween 80 at a concentration of 3% w/v. The aqueous dispersion was shaken with a
mechanical stirrer for 30 min in a water bath at the constant temperature of 37  C. In order to obtain
small unilamellar vesicles from multilamellar vesicles, an ultrasonication probe was used for 10 min
(with pulsed duty cycles of 12 s on and
1
2 s off, amplitude 50%) with the sample in an ice bath to prevent
lipid degradation [29]. Finally, a gentle centrifugation of 1 min at 1205⇥ gwas performed to remove
possible metallic particles released by the ultrasonic probe inside the liposomal dispersion [30].
In addition, for CLPs, 10 mg of DDAB were weighted together with P90G and CHOL and then
vesicles were prepared by hydrating the dry lipid film with 10 mL PBS containing 3% of Tween 80 [31].
AG-loaded LPs (LPs-AG) and AG-loaded CLPs (CLPs-AG) were prepared with the same method
described above, adding 8.5 mg of AG (0.85 mg/mL, corresponding to 5% of the weight of the lipid
component) together with P90G, CHOL, DDAB in the case of CLPs-AG and 1–2 mL of methanol with
dichloromethane to completely dissolve AG.
Coumarin-6-loaded liposomes (LPs-6C and CLPs-6C) were prepared using the same method,
adding 5 mg of the probe ( max = 444,  ex = 420 nm,  em = 505 nm, green), corresponding to 3% of the
weight of the lipid component, to the organic phase.
2.3. Physical and Morphological Characterization
Liposomes’ hydrodynamic diameter, size distribution and ⇣-potential were measured by Light
Scattering (LS), using a Zsizer Nano series ZS90 (Malvern Instruments, Malvern, UK) outfitted with
a JDS Uniphase 22 mWHe-Ne laser operating at 632.8 nm, an optical fiber-based detector, a digital
LV/LSE-5003 correlator and a temperature controller (Julabo water-bath) set at 25  C. Time correlation
functions were analyzed by the Cumulant method, to obtain the hydrodynamic diameter of the vesicles
(Zaverage) and the particle size distribution (polydispersity index, PdI) using the ALV-60 ⇥ 0 software
V.3.X provided by Malvern. ⇣-potential, instead, was calculated from the electrophoretic mobility,
using the Henry correction to Smoluchowski’s equation. The samples were diluted 100-fold in distilled
water and an average of three measurements at stationary level was taken. A Haake temperature
controller kept the temperature constant at 25  C.
Liposomes were also analyzed in terms of morphology, shape, and dimensions by the transmission
electron microscopy (TEM). The aqueous dispersion was diluted 10-fold in PBS and 5 µL were applied
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to a carbon film-covered copper grid. Most of the sample was blotted from the grid with filter paper to
form a thin film. After the adhesion of liposomes, 5 µL of phosphotungstic acid solution (1% w/v in
sterile water) were dropped onto the grid as a staining medium and the excess solution was removed
with filter paper. Samples were dried for 3 min, after which they were examined with a JEOL 1010
electron microscope and then photographed at an accelerating voltage of 64 kV.
2.4. Chemical Characterization of Formulations
The percentage of the AG or 6C entrapped into liposomes in respect to the amount of substances
initially used in the liposomal preparation was expressed as encapsulation efficiency (EE%) and
calculated using the direct method. Free AG or 6Cwas removed bymeans of dialysis. 2 mL of liposomal
suspensions were transferred in a dialysis bag (cut-off 3500–5000 Dalton), which was stirred in 1 L
of water at room temperature for 1 h [29]. The content of AG or 6C entrapped within liposomes was
quantified by HPLC-DAD analysis, respectively after disruption with methanol of purified liposomes
(placed in the ultrasonic bath for 30 min) and ultracentrifugation for 10 min at 11,330⇥ g.
LC% for liposomal formulations was calculated using the following Equation (1):
LC% =
Total amount of determined drug
Weight of liposomes
⇥ 100 (1)
The Recovery% was carried out with the same procedure but without initial dialysis and was
calculated using the following Formula (2):
Recovery% =
Total amount of determined drug
Initial amount of drug loading
⇥ 100 (2)
2.5. HPLC-DAD and HPLC-FLD Methods
An HP 1100 liquid chromatograph equipped with a DAD detector was used to carry out the
quali-quantitative determinations of AG. A 150 mm ⇥ 4.6 mm i.d., 5 µm Zorbax Eclipse XDB,
RP18 column (Agilent Technologies, Santa Clara, CA, USA) was employed. The mobile phases
were (A) CH3CN and (B) formic acid/water pH 3.2. Flow rate was 0.8 mL/min and temperature
were set to 27  C. The following gradient profile was utilized: 0–2 min, 5–15% A, 95–85% B; 2–5 min,
15% A, 85% B; 5–7 min 15–50% A, 85–50% B; 7–12 min, 50% A, 50% B; 12–15 min, 50–30% A, 50–70% B;
15–20 min, 30% A, 70% B; 20–25 min, 30–5% A, 70–95% B with equilibration time of 5 min. Injection
volume was 10 µL. The UV/vis spectra were recorded in the range 200–800 nm and the chromatograms
were acquired at 223 nm.
6C characterization was performed using an HP 1200 liquid chromatograph with Luna RP18
column (4.6 mm ⇥ 250 mm i.d., 5 µm) maintained at 25  C. The mobile phase was composed of (A)
CH3CN and (B) formic acid/water pH 3.2 with a flow rate of 1 mL/min. The gradient profile was:
0–2 min, 30% A, 70% B; 2–26 min 30–100% A, 70–0% B; 26–29 min 100% A, 0% B; 29–35 min 100–30% A,
0–70% B with post-time of 5 min. Chromatograms were acquired at 444 nm.
An HP 1200 liquid chromatograph equipped with a FLD detector was used for the quantification
of NaF probe ( ex = 460 nm,  em = 515 nm, green). The column was a Kinetex C18 (4.6 mm ⇥ 150 mm
i.d., 5 µm) maintained at 27  C. The mobile phases were (A) CH3CN and (B) formic acid/water pH
3.2. Flow rate was 0.8 mL/min and the injection volume was 10 µL. The following gradient profile
was utilized: 0–3 min, 20% A, 80% B; 3–23 min, 20–80% A, 80–20% B; 23–25 min 80–100% A, 20–0% B;
25–27 min, 100–20% A, 0–80% B with equilibration time of 5 min.
Diluting stock solutions in CH3OH (0.5 mg/mL for AG and 0.1 mg/mL for 6C) and in H2O
(0.1 mg/mL for NaF), standard solutions were freshly prepared. To quantify each compound,
an external standard method was applied using a regression curve and analyses were performed in
triplicate. Results were expressed as the mean ± SD of the 3 experiments.
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All the compounds showed a linear response: AG from 0.05 to 25 µg/mL, NaF from 0.05 to
46 µg/mL and 6C from 0.515 to 51.5 µg/mL. All the curves had coefficients of linear correlation
R2   0.999.
Progressive dilutions of standard solutions were used to calculate the limit of detection LOD
(S/N   3) and the limit of quantification LOQ (S/N   10). LOD and LOQ for AG were 2.6 ng and
5.3 ng, respectively.
2.6. Stability Studies
The stability of empty and AG-loaded liposomes was studied for one month. Aqueous
dispersions were kept at 4  C and, at fixed time intervals, their physical and chemical stabilities
were assayed: physical stability was checked by monitoring sizes, polydispersity index and
⇣-potential, while chemical stability was determined by quantification of encapsulated drug by
HPLC-DAD analysis.
The freeze-drying process in the absence of cryoprotectant and in the presence of 1% w/v of
glucose or sucrose was also considered. Afterwards, lyophilization physical stability was checked for
one month at 25  C.
200 µL of LPs and CLPs dispersions were incubated at body temperature with a solution of
human serum albumin (HSA, 40 mg/mL in PBS) for two hours under magnetic stirring to mimic
in vivo conditions [32,33]. Physical stability of the formulations was evaluated using Dynamic Light
Scattering, by controlling liposomes sizes at regular intervals.
The yield of the preparation of freeze-dried LPs-AG and CLPs-AG was calculated as the weight
of the product obtained after the freeze-drying, compared to the weight of the components used in the
reaction (3):
Yield% =
real weight (mg)
teoric weight (mg)
⇥ 100 (3)
2.7. In Vitro Release
AG in vitro release from liposomes was performed using a dialysis membrane
(cut-off 3000–5000 Dalton) in PBS at 37  C. Two mL of AG solution (0.85 mg/mL in methanol), LPs and
CLPs suspensions were filled in pre-soaked dialysis tubes and placed in 200 mL of release medium
using a magnetic stirrer. An aliquot of 1 mL of release medium was removed at pre-determined time
intervals and replaced with 1 mL of fresh PBS maintained at 37  C [34]. AG concentration at different
times was calculated using HPLC analyses: the mean of triplicate drug release and standard deviation
(mean ± SD, n = 3) was used to draw the drug release profiles.
The following Formula (4) was applied to calculate the percentage of AG released in the medium
at pH 7.4 at each time interval (0, 30, 60, 120, 240, 360 and 1440 min):
% drug released =
drug(t) (mg)
total drug (mg)
⇥ 100 (4)
To evaluate the kinetics and mechanism of drug release from the liposomes,
the Korsmeyer–Peppas model, Hixson Crowell model, Higuchi model, first order and zero
order mathematical models were used and the best fitted model was selected based on high regression
coefficient (R2) value for the release data.
2.8. PAMPA Studies
PAMPA studies for LPs-AG and CLPs-AG were carried out using the method previously
published [11]. A solution (2% w/v) of Porcine Polar Brain Lipid (PBL) in n-dodecane was prepped and
the mixture was sonicated. PBL solution (5 µL) was added to each donor plate well [16]. Right after the
application of the artificial membrane, 250 µL of formulation were added to each donor compartment,
whilst the acceptor compartment was filled with PBS/Ethanol solution. Then the drug-filled donor
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compartment was installed into the acceptor plate. After incubation for 18 h, the donor and acceptor
plate samples were withdrawn and analyzed by HPLC-DAD analyses for quantification of AG
concentration: 150 µL were taken from both compartments, later diluted with methanol, placed in the
ultrasonic bath for 30 min and finally ultra-centrifuged for 10 min at 11,330⇥ g (4  C). The permeability
of AG was calculated using the following Formula (5) [35]:
Pe =  ln [1   CA(t)/Cequilibrium]/A ⇥ (1/VD + 1/VA) ⇥ t (5)
where Pe is permeability in the unit of cm/s, effective filter area (A) = f ⇥ 0.3 cm2, where f = apparent
porosity of the filter, CA(t) = compound concentration in receptor well at time t, VD = donor well
volume (mL), VA = receptor well volume (mL), t = incubation time (s), CD(t) = compound concentration
in donor well at time t, and (6)
Cequilibrium = [CD(t) ⇥ VD + CA(t) ⇥ VA]/(VD + VA) (6)
The experiments were performed in triplicate.
2.9. hCMEC/D3 Cell Culture
This cell line (Millipore Cat. # SCC066) derives from human temporal lobe micro-vessels isolated
from tissue excised during surgery for epilepsy control. Cells were seeded in a concentration of
2.5 ⇥ 104 cells/cm2 and grown at 37  C in an atmosphere of 5% CO2 in 25 cm2 rat tail collagen type I
coated culture flasks. EndoGROTM-MV Complete Media Kit (Cat. # SCME004) supplemented with
1 ng/mL FGF-2 (Cat. #GF003) was changed every three days and cells were grown until they were
90% confluent. Cells were passaged at least twice before use. Confluent hCMEC/D3 cells were split by
AccumaxTM Cell Counting Solution in DPBS.
2.10. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) Assay
To assess cell viability after AG and LPs-AG and CLPs-AG exposure, an MTT assay was
performed [36,37]. Cells were seeded in a 24-well plate (6 ⇥ 104 cells/cm2) pre-coated with Collagen
Type I, Rat Tail (Cat. #08–115) and grown at 37  C in an atmosphere of 5% CO2 in EndoGROTM Basal
Medium (EBM-2). When the cells were approximately 70–80% confluent they were incubated with
different concentrations of AG (10 and 100 µM), LPs-AG (0.085 and 0.0085 mg/mL) and CLPs-AG
(0.085 and 0.0085 mg/mL), obtained by dilution (1:10 and 1:100) of the formulation in EBM-2 for 2,
4 and 24 h. The liposome formulations were previously filtered through 0.4 µm sterile filter units.
The medium of each well was separated from the cells and stored for lactate dehydrogenase (LDH)
assay, and cells were treated with 1 mg/mL of MTT for 1 h at 37  C and 5% CO2. Finally, DMSO was
added to dissolve MTT formation and absorbance was measured at 550 and 690 nm. Cell viability
was expressed as a percentage compared to the cells incubated only with EBM-2 (positive control).
Triton X-100 was used in the MTT assay as the negative control since its detergent action disrupts
the cells.
2.11. LDH Assay
Cytotoxicity after AG and liposomes exposure was verified with LDH assay. The medium
resulting from incubation of AG and liposomes with cells was centrifuged (250⇥ g, 10 min at RT) and
the supernatant separated from the deposited cells in each well. This centrifugation process allowed
us to remove any waste and cellular debris as well as AG and liposomes. The release of LDH into
culture supernatants was detected by adding catalyst and dye solutions of a Cytotoxicity Detection Kit
(LDH) (Roche Diagnostics, Indianapolis, IN, USA). The absorbance values were recorded at 490 nm
and 690 nm. Cytotoxicity was expressed as a percentage compared to the maximum LDH release in the
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presence of triton X-100 (positive control). EBM-2 was used as negative control since no cytotoxicity
was detected in such conditions.
2.12. hCMEC/D3 Cell Culture for Transwell Permeability Studies
High density pore (2 ⇥ 106 pores/cm2) transparent PET membrane filter inserts (0.4 µm, 23.1 mm
diameter, Falcon, Corning BV, Amsterdam, Netherlands) were used in 6-well cell culture plates (Falcon,
Corning, Amsterdam, Netherlands) for all transcytosis assays. The transparent PET membrane filter
inserts were coated with rat tail collagen type I at a concentration of 0.1 mg/mL and incubated at 37  C
for 1 h prior to cell barrier coating. Inserts were subsequently washed with PBS and incubated for 1 h,
after which PBS was removed and replaced with the assay medium. The inserts were calibrated for at
least 1 h with assay medium at 37  C. Optimummedia volumes were calculated to be 1 mL and 1.2 mL
respectively for apical and basolateral chambers. The transwell inserts were calibrated with assay
medium for 1 h, then the medium was removed and hCMEC/D3 cells were seeded onto the apical
side of the inserts at a density of 6 ⇥ 104 cells/cm2 in 1 mL assay media. 1.2 mL of fresh medium was
added to the basolateral chamber. The assay medium was changed every 3 days following transwell
apical insert seeding with hCMEC/D3. For seven days, cells were grown to confluence. hCMEC/D3
monolayers were used as a permeability assay for AG and AG-loaded liposomes. Fluorescein sodium
salt (NaF) was considered at a concentration of 10 µg/mL as an integrity control marker with a
known permeability coefficient (Papp) for this cell line [19]. The integrity of monolayer cells was
confirmed also by observation of cultures under phase-contrast microscopy or under bright-field
optics using of transparent membranes. The image was observed using an inverted microscope
(Olympus IX-50; Solent Scientific, Segensworth, Fareham, UK) with a low-power objective (20X).
The images were digitized using a video image obtained with a CCD camera (Diagnostic Instruments
Inc., Sterling Heights, MI, USA) controlled by software (InCyt Im1TM; Intracellular Imaging Inc.,
Cincinnati, OH, USA).
For permeability studies, AG (10, and 100 µM), LPs-AG and CLPs-AG (0.085 mg/mL,
corresponding to AG 240 µM) obtained by dilution 1:10 of the formulation in EBM-2 were tested
and incubated for 1, 2, 3 and 4 h in the apical donor compartment. At the end of the incubation, the
amount of NaF and AG were quantified both in apical and basolateral compartments by HPLC-FLD or
HPLC-DAD method. In the case of the formulation, EBM-2 was diluted with methanol and placed
in the ultrasonic bath for 30 min and then ultra-centrifuged for 1 h at 11,330⇥ g (4  C). The apparent
permeability coefficients (Papp) of free AG and AG encapsulated in LPS and CLPs were calculated
according to the Equation (7):
Papp (cm/s) = VD/(A·MD) ⇥ (DMR/Dt) (7)
where: VD = apical (donor) volume (cm3), MD = apical (donor) amount (mol), DMR/Dt = change in
amount (mol) of compound in receiver compartment over time.
The recovery for AG and NaF was calculated according to the Equation (8) [19]:
Recovery (%) = CDf·VD + CRf ·VR/(CD0·VD) ⇥ 100 (8)
where CDf and CRf are the final compound concentrations in the donor and receiver compartments,
CD0 is the initial concentration in the donor compartment and VD and VR are the volumes in the donor
and receiver compartments, respectively. All experiments were performed at least in triplicate.
2.13. Cellular Uptake of LPs-6C and CLPs-6C
For the evaluation of the intracellular content of 6-Coumarin, hCMEC/D3 cells (1 ⇥ 104) were
exposed for 2 h to the LPs-6C and CLPs-6C loaded with 0.5 mg/mL of 6C and diluted 1:100 into
EBM-2, and to a saturated solution of fluorescent probe. To elucidate the endocytic uptake mechanisms,
these experiments were carried out in presence/absence of endocytic inhibitors. Control cells were
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exposed to liposomal formulations without any agent pre-treatment and their uptake was assumed to
be 100%. A second group of cells was pre-treated with 15 µM chlorpromazine for 30 min followed by
incubation with liposomes. A third group of cells was pre-treated with 25 µM of indomethacin for
30 min; and, finally, a fourth group of cells was maintained at 4  C during the LPs-6C and CLPs-6C
exposure to observe the effect of low temperature, a general metabolic inhibitor.
At the end of the treatments, the amount of 6C was quantified on cellular lysate by HPLC.
For control cells and cells maintained at 4  C during exposure, a morphological evaluation of cellular
uptake was also performed: hCMEC/D3 cells were cultured on histological slides, treated as described
above, fixed in 4% formaldehyde in 0.1 mol/L phosphate buffer, pH 7.4, for 10 min then stained with
Fluoro scheld with DAPI (Sigma, Milan, Italy) to display the nucleus and observed by fluorescence
microscopy (Labophot-2 Nikon, Tokyo, Japan). Ten photomicrographs were randomly taken for
each sample.
Cellular uptake was investigated by confocal microscopyNikon Eclipse Ti using liposomes labeled
with 6C, with S Fluor 20x, NA = 0.75 high pressure Hg vapor lamp (Intensilight, Nikon, Tokyo, Japan).
Filter set: excitation 365 nm emission 400 nm hi-pass DAPI, excitation 485 nm emission 524 nm
6Co and CCD camera: Coolsnap HQ2, Princeton instruments, Trenton, NJ, USA, 1392 ⇥ 1040, 6.45 um
square pixels.
2.14. Statistical Analysis
The experiments were repeated three times and results expressed as a mean ± standard deviation.
Statistical significance of hCMEC/D cell viability and cellular uptake was analyzed using one-way
ANOVA followed by the post hoc Tukey’s w-test for multiple comparisons. All statistical calculations
were performed using GRAPH-PAD PRISM v. 5 for Windows (GraphPad Software, San Diego, CA,
USA). A probability value (p) of <0.05 was considered significant.
3. Results and Discussion
3.1. Preparation and Characterization of Liposomes
LPs were prepared by using P90G, CHOL and Tween 80. This compound was selected as a
coating agent to increase the stability of the formulation, to produce “stealth” nanovesicles and to
promote endocytosis of the carrier at the level of cerebral endothelial cells [23]. Various ratios of the
two lipid constituents were tested to obtain small sizes, good polydispersity and favorable ⇣-potential.
In particular, the ratios P90G:CHOL 18:1, 16:1, 14:1, 12:1, and 10:1 were considered. The best ratio
resulted to be 16:1, corresponding to 160 mg of P90G and 10 mg of CHOL. Then, 3% w/v of Tween
80 was added (LPs). Furthermore, different sonication times were tested to optimize LPs physical
characteristics. The selected conditions consisted in two cycles of 5 min of sonication, each including
0.5 s of sonication alternating with 0.5 s of pause, as reported in the materials and methods section.
LPs were nanosized unilamellar vesicles, with a PdI less than 0.25 and a ⇣-potential, around  20 mV
(Table 1), confirming a homogeneous and stable dispersion. LC% was 2.28% ± 0.22. The mean vesicle
sizes and the width of the particle distribution are important parameters as they govern physical
stability and permeation through BBB [38]. Moreover, the vesicles sizes highly affected the interaction
of the liposomes with the hCMEC/D3 cellular model [39,40].
AG does not influence the stability of the formulation (Table 1); when LPs were loaded with AG,
LPs-AG showed the same physical parameters as LPs. The electron microscope analysis confirmed
the liposomal structure; the results evidenced the presence of spherical vesicles, with a defined
phospholipid bilayer, well separated, due to the presence of the surfactant that prevents agglomeration,
and with dimensions around 100 nm, confirming the DLS results (Figure 1a).
Next, LPs were functionalized with positive surface charges by using DDAB (cationic liposomes,
CLPs) in the same amount of CHOL (10 mg in the total formulation). In this case, ⇣-potential resulted
positive, indicating the presence of positive charges on the surface of the carrier.
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Then, CLPs loaded with 8.5 mg of AG (corresponding to 5% of the weight of the lipid component)
were prepared (CLPs-AG); the presence of DDAB and AG did not modify the physical characteristics
of the formulation (Table 1). LC% was 3.08% ± 0.21. TEM analysis showed well separated spherical
shape vesicles, with a distinct phospholipid bilayer (Figure 1b).
The compound 6-Coumarin (6C), a lipophilic fluorescent dye, was incorporated into liposomes
to investigate the ability of nanoparticles to penetrate into hCMEC/D3 cells, as BBB-model, and to
elucidate trans-endothelial transport in vitro. The preparation of fluorescent liposomes was performed
as reported for LPs and CLPs, by adding 6C (0.5 mg/mL) to the organic phase. Their physical and
chemical parameters are shown in Table 1. The same dimensions of the two types of liposomes,
was very important to interact with the HCMEC/D3 equally [39]. LPs-6C and CLPs-6C resulted larger
but useful for a parenteral administration. AG and 6C are lipophilic compounds and there are inserted
in the bilayer, but the effect on the sizes of nanoparticles is different due to their unlike chemical
structure. The high ⇣-potential of all formulations is indicative of their stability, as also supported by
stability studies.
Table 1. Physical characterization of empty, andrographolide (AG) and coumarin-6 (6C)
loaded liposomes.
Sample Size (nm) PdI ⇣-Potential EE% Recovery%
LPs 80.2 ± 3.6 0.22 ± 0.03  20.4 ± 4.1 - -
CLPs 84.6 ± 8.1 0.23 ± 0.02 20.7 ± 4.7 - -
LPs-AG 96.4 ± 9.5 0.23 ± 0.03  22.8 ± 1.2 44.7 ± 3.2 91.1 ± 5.3
CLPs-AG 82.1 ± 9.3 0.25 ± 0.01 20.3 ± 3.7 47.5 ± 3.3 94.9 ± 4.7
LPs-6C 193.1 ± 3.0 0.21 ± 0.02  27.4 ± 0.4 46.0 ± 1.4 71.2 ± 4.2
CLPs-6C 197.1 ± 1.4 0.27 ± 0.03 31.1 ± 0.6 63.1 ± 0.1 80.6 ± 5.0
LPs: liposomes with Tween 80, CLPs: liposomes with Tween 80 and DDAB. Data displayed as mean ± SD; n = 3.
Pharmaceutics 2018, 10, x FOR PEER REVIEW  9 of 19 
 
t  trans-endothelial transport n vitro. The preparation of fluorescent lipo omes was 
pe formed as reported for LPs an  CLPs, by adding 6C (0.5 mg/mL) to the organ c a e. Their 
p ysical and ch mical parameters are shown in Table 1. The ame dimensions of the two types of 
liposomes, was very important to interact with the HCMEC/D3 equally [39]. LPs-6C and CLPs-6C 
result d larger but us fu  for a parenteral administration. AG and 6C are lipophilic compounds an  
there are inserted in th  bilayer, but th  effect on the sizes of nanoparticl s is differe t due to their 
unlike chemical structur . The high ζ-potential of all formulations is indicative of their stability, as 
also supported by stability studies. 
Table 1. Physical char cterization of empty, andrographolide (AG) an  coumarin-6 (6C) loaded liposomes. 
Sample Size (nm) PdI ζ-Potential EE% Recovery% 
LPs 80.2 ± 3.6 0.22 ± 0.03 −20.4 ± 4.1 - - 
CLPs 84.6 ± 8.1 0.23 ± 0.02 20.7 ± 4.7 - - 
LPs-AG 96.4 ± 9.5 0.23 ± 0.03 −22.8 ± 1.2 44.7 ± 3.2 91.1 ± 5.3 
CLPs-  82.1 ± 3 5  1 20.3 ± 3.7 7.5 ± 3 94.9 ± 4.7 
LPs-6C 193.1 ± 3.0 0.21 ± 0.02 −27.4 ± 0.4 46.0 ± 1.4 71.2 ± 4.2 
CLPs-6C 197.1 ± 1.4 0.27 ± 0.03 31.1 ± 0.6 63.1 ± 0.1 80.6 ± 5.0 
LPs: liposomes with Tween 80, CLPs: liposomes with Tween 80 and DDAB. Data displayed as mean 
± SD; n = 3. 
 
Figure 1. TEM images of LPs-AG (a) and CLPs-AG (b) (scale 100 nm). 
3.2. Stability Studies 
Liposomes stability was evaluated both as a colloidal dispersion and in the freeze-dried form. 
The ability of the aqueous dispersions to maintain their physicochemical properties in terms of 
particle size, PdI, surface charge and drug entrapment was assessed after 1-month storage at 4 °C and 
the Light Scattering analyses were performed to control the stability over time. No significant changes 
were observed in physical parameters of empty or LPs-AG and CLPs-AG dispersions (Figure 2). The 
presence of non-ionic surfactant is expected to reduce the agglomeration between liposomes via steric 
repulsion. Also, the presence of DDAB on the surface of liposomes prevented the aggregation and 
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efficiency remained constant, around 45%. 
The major limitation to liposomes use is due to their physical and chemical instability, when the 
aqueous suspension is stored for an extended period. The poor stability in an aqueous medium forms 
a real obstacle against the clinical application of nanoparticles. 
To improve the physical and chemical stability, water needs to be removed. Freeze-drying is a 
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Figure 1. TEM images of LPs-AG (a) and CLPs-AG (b) (scale 100 nm).
3.2. Stability Studies
Liposomes stability was evaluated both as a colloidal dispersion and in the freeze-dried form.
The ability of the aqueous dispersions to maintain their physicochemical properties in terms of particle
size, PdI, surface charge and drug entrapment was assessed after 1-month storage at 4  C and the
Light Scattering analyses were performed to control the stability over time. No significant changes
were observed in physical parameters of empty or LPs-AG and CLPs-AG dispersions (Figure 2).
The presence of non-ionic surfactant is expected to reduce the agglomeration between liposomes via
steric repulsion. Also, the presence of DDAB on the surface of liposomes prevented the aggregation
and the precipitation of the vesicles and increased the systems stability. In addition, the entrapment
efficiency remained constant, around 45%.
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The major limitation to liposomes use is due to their physical and chemical instability, when the
aqueous suspension is stored for an extended period. The poor stability in an aqueous medium forms
a real obstacle against the clinical application of nanoparticles.
To improve the physical and chemical stability, water needs to be removed. Freeze-drying is a
good technique to enhance the chemical and physical stability of formulations over prolonged periods.
The stability of LPs-AG and CLPs-AG with time was evaluated also in the freeze-dried form.
However, the freezing process of the sample might cause problems of possible structural and/or
functional damages of the system, and/or subsequent difficulties in sample re-solubilization, due to
particle aggregation phenomena. The addition of cryoprotectants improves the quality of the
dehydrated product, decreases particle aggregation phenomena and allows to obtain an easier
re-dispersion of the freeze-dried product.
Therefore, to estimate the effect of the presence and type of cryoprotectant, empty, LPs-AG and
CLPs-AG formulations were freeze-dried with and without sucrose or glucose (1% w/v). After the
lyophilization process, all formulations were dispersed in PBS and analyzed by DLS and ELS (Table 2).
As shown in Table 2, the drying process produced an increase in terms of size and PdI, respect to
the values reported before the freeze-drying process (Table 1). However, all liposomes maintained
characteristics suitable for parenteral administration. The best freeze-drying process was obtained in
the presence of glucose both for LPs-AG and CLPs-AG. The EE% remained almost constant around
43%. The yield % of the preparation process was also calculated, in this case without addition of the
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cryoprotectant, and resulted 69.5% ± 0.1 for LPs and 71.2% ± 0.1 for CLPs (mean ± SD; n = 3). After a
month of storage at 25  C the freeze-dried product retained the starting characteristics.
Table 2. Physical parameters of andrographolide loaded liposomes, after the freeze-drying process
with and without cryoprotectant, 1% w/v of sucrose or glucose.
LPs-AG No Cryoprotector Glucose Sucrose
Size (nm) 148.8 ± 1.4 135.0 ± 0.9 147.5 ± 1.2
PdI 0.32 ± 0.03 0.25 ± 0.02 0.35 ± 0.01
⇣ (mV)  21.3 ± 0.9  19.4 ± 1.1  18.5 ± 1.0
CLPs-AG
Size (nm) 144.6 ± 2.2 131.3 ± 5.1 149.3 ± 1.2
PdI 0.38 ± 0.02 0.28 ± 0.01 0.29 ± 0.01
⇣ (mV) +28.6 ± 0.9 +27.0 ± 0.8 +26.5 ± 0.9
LPs-AG: liposomes with Tween 80 loaded with AG, CLPs-AG: liposomes with Tween 80 and DDAB loaded with
AG. Data displayed as mean ± SD; n = 3.
A drawback to the use of nanocarriers, in particular cationic nanocarriers, for brain delivery is
their binding to serum proteins that attenuates their surface charge. Therefore, the stability of LPs-AG
and CLPs-AG in presence of human serum albumin (HSA) at physiological concentration was also
tested. After 2 h of incubation, DLS analyses confirmed that sizes were not affected by the presence of
HSA and therefore revealed coexistence of free serum proteins and optimized nanocarrier without any
protein corona effect (Table 3).
Table 3. Physical stability of LPs-AG and CLPs-AG in presence of human serum albumin.
LPs-AG CLPs-AG
Time Size (nm) Pd Size (nm) Pd
0 94.8 ± 2.4 0.23 ± 0.02 76.4 ± 1.2 0.24 ± 0.01
30’ 103.8 ± 2.0 0.39 ± 0.01 82.9 ± 0.5 0.41 ± 0.02
1 h 97.2 ± 3.2 0.39 ± 0.02 83.5 ± 4.8 0.40 ± 0.01
2 h 99.1 ± 5.1 0.39 ± 0.01 81.9 ± 3.4 0.43 ± 0.02
LPs-AG: liposomes with Tween 80 loaded with AG, CLPs-AG: liposomes with Tween 80 and DDAB loaded with
AG. Data displayed as mean ± SD; n = 3.
3.3. In Vitro Release
AG in vitro release at 37  C from LPs-AG and CLPs-AG was evaluated for 24 h by using a dialysis
bag and PBS as receptor medium to mimic sink conditions. The release profiles of AG from AG
solution, LPs-AG and CLPs-AG were reported in Figure 3. The result indicated that the release of AG
from methanol solution through the dialysis membrane was much faster, with a fast release during the
first 2 h and approximately 100% of the drug released within 6 h. In contrast, the immediate release
of the drug (burst effect) does not occur in the case of LPs-AG and CLPs-AG. The percentages of
AG released from LPs and CLPs were gradual: only 56.8% and 69.7% of drug was released within
6 h, respectively. The percentages rose to 83.5% and 77.4%, after 24 h, respectively. The almost linear
and gradual trend of the release indicated that the liposomal systems can release AG for prolonged
periods and in greater quantities compared to the saturated aqueous solution, were the solubility of AG
resulted very low (0.05 mg/mL). Optimized liposomal formulations are able to solubilize 0.85 mg/mL
of drug.
Different theoretical models were considered to examine the nature of release. The drug release
mechanism was defined by fitting AG release data with various kinetics models. By comparing the
regression coefficient values, the Higuchi model (R2 = 0.8366 and 0.9264, respectively, Table 4) resulted
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as the best to describe the kinetics of these two types of liposomes. Thus, the liposomal membrane
disruption controlled the release mechanism [41].Pharmaceutics 2018, 10, x FOR PEER REVIEW  12 of 19 
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Table 4. Regression coefficient (R2) obtained in different kinetics models for AG release from LPs-AG
and CLPs-AG.
Release Kinetics LPs-AG CLPs-AG
Zero order 0.5722 0.7079
First order 0.7685 0.8816
Korsmeyer-Peppas 0.4552 0.4980
Hixson 0.7033 0.8292
Higuchi 0.8366 0.9264
LPs-AG: liposomes with Tween 80 loaded with AG, CLPs-AG: liposomes with Tween 80 and DDAB loaded with G.
Due to the very low solubility of AG in water and the related problems of bioavailability, both the
liposomal formulations allow the administration of a high amount of solubilized molecule according
to the requirements for parenteral preparations.
3.4. PAMPA Study
Parallel Artificial Membrane Permeability Assay (PAMPA) was performed to estimate passive
transcellular permeability. It is a non-cell-based permeability model because it lacks transporter-
and pore-mediated permeability, but is considered robust, reproducible and it results in a helpful
complement to the cellular permeability model for its speed, low cost and versatility, and readily
provides information about passive transport permeability.
AG is a molecule with low BBB permeability (effective permeability, Pe value of
0.49 ± 0.16 ⇥ 10 6 cm/s [11] and therefore liposomal formulation could represent a useful tool
to improve its permeation. Pe of AG-loaded liposomes resulted as increased, in particular
3.94 ± 0.60 ⇥ 10 6 cm/s for LPs-AG and 3.87 ± 0.36 ⇥ 10 6 cm/s for CLPs-AG. These values
confirmed that LPs-AG and CLPs-AG increased the permeability of the drug, of about an order
of magnitude, compared to the aqueous solution.
Though this test does not discriminate the different behavior of the two systems because the
artificial membrane fails to mimic all properties of a cell, a mechanism of permeation through the
artificial membrane was hypothesized. An interaction between the phospholipid bilayer, which is a
flexible system, with the lipid that covers the artificial membrane, similar to one of mechanisms of
liposome-cell interaction.
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3.5. MTT and LDH Assays
MTT and LDH assays were performed in the hCMEC/D3 cell line to evaluate the effect of AG and
LPs-AG and CLPs-AG in cell viability and cytotoxicity, and permeability studies were also conducted
in transwell devices using the same cell line. The in vitro cytotoxicity of the developed LPs-AG and
CLPs-AG and AG was assessed by cell viability determination and membrane integrity evaluation
using the hCMEC/D3 cell line in MTT and LDH assays, respectively (Figure 4). When cells were
exposed to different concentrations of AG (10 and 100 µM) and LPs-AG and CLPs-AG (0.0085 and
0.085 mg/mL) for 2 (Figure 4a) and 4 h (Figure 4b), no significant changes were observed in MTT
metabolization, except for LPs-AG and CLPs-AG (0.085 mg/mL) or LDH release when compared to
cells exposed to the EBM-2 medium alone, indicating that AG and LPs-AG and CLPs-AG affected
neither the metabolic activity of the cells nor the membrane integrity at these time points. On the other
hand, when the cells were incubated for 24 h with AG at a dose of 100 µM, LPs-AG (0.085 mg/mL)
and CLPs-AG (0.0085 and 0.085 mg/mL) we observed a significant reduction of cell viability and an
increase in cytotoxicity compared to the control (Figure 4c).
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Figure 4. hCMEC/D3 cell viability evaluated by MTT assay (left panel) and cytotoxicity by LDH assay
(right panel) when exposed for 2 h (a), 4 h (b) and 24 h (c) to AG (10 and 100 µM) or LPs-AG and
CLPs-AG (0.0085 and 0.085 mg/mL). Data is expressed as percentage of control (EBM-2 medium)
and Triton-X (TTX) which represent, respectiv ly, the maximum cell v ability and cell cytotoxicity.
Values represent the mean ± SEM of at least three experiments performed in triplicate. * p < 0.05 and
** p < 0.01 vs. EBM-2 alone.
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3.6. BBB Permeability Studies
hCMEC/D3 brain microvascular endothelial cell line is a model of human BBB utilized to study
the drug transport mechanisms [18,42]. The cells retain the expression of most transporters and
receptors expressed in vivo in the human BBB. hCMEC/D3 apparent permeability coefficient (Papp)
correlates well with in vivo permeability data, and therefore permeability studies were performed to
predict the permeability of free AG and LPs-AG and CLPs-AG across the BBB. NaF was used as the
negative control and its Papp was determined during all transport experiments to monitor the integrity
of the cell layer. This aspect was also been checked by phase-contrast microscopy [11].
Papp of NaF was 8.27 ± 1.81 ⇥ 10 6 cm/s, in agreement with the literature values [11,12,19].
This value remained constant during the permeability assay, and demonstrates the confluence of
the monolayer and assesses the tight junction integrity. Papp of LPs-AG and CLPs-AG were only
slightly higher than the Papp values of the free AG for the first 3 h. However, at 4 h, the Papp
value for both LPs-AG and CLPs-AG was significantly higher (about double) than that of the free
AG (Papp of AG: 8.67 ± 0.95 ⇥ 10 6 cm/s; Papp LPs-AG: 16.8 ± 1.70 ⇥ 10 6 cm/s; Papp CLPs-AG:
17.2 ± 1.43 ⇥ 10 6 cm/s). The amount of AG that permeated when loaded into liposomes increased
about 200 times in respect to the free molecule, as confirmed by the increase of the Papp values
during the time reported in Figure 5. AG transport across the cell was in a time-dependent manner.
The obtained Papp data are useful for in vitro prediction, as confirmed by the recovery value, which was
above 80% in all experiments. The data agrees with PAMPA results.
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Figure 5. The apparent permeable coefficient of different liposomal formulations for different treatment
time in the in vitro BBB model. (Data represent means ± S.D, n = 3).
A combination assay of PAMPA and unidirectional (apical to basal) hCMEC/D3 permeability
model can synergistically provide invaluable permeability/absorption assessment of AG. The Papp
values are greater than those of Pe, due to the presence of an active endocytic mechanism in addition
to a passive one, as seen by following uptake studies.
3.7. Liposome Uptake by hCMEC/D3 Cells
Figure 6 shows the fluorescence images of hCMEC/D3 cells treated with LPs-6C and CLPs-6C
after 2 h of incubation. The images revealed that the probe was internalized and LPs-6C and CLPs-6C
were punctually concentrated in intracellular vesicles (endosomes or lysosomes) which can be related
to their endocytic mechanism of uptake [42]. Besides their cytoplasmic location, green fluorescence
indicates that nanoparticles were also transported to the perinuclear area. This is an important finding
for pharmaceutical drug delivery research, since the nucleus is the target site for several drugs [43].
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Concerning the uptake of liposomes by hCMEC/D3 cells, it was different for both liposomes
LPs-6C and CLPs-6C: 6.4% and 14.0%, respectively. The result proves that the internalization ability of
liposomes increases in the presence of positive charge on the bilayer that improves the binding affinity
between carrier and cellular membrane [31].
Furthermore, a group of cells was maintained at 4  C in the presence of LPs-6C and CLPs-6C,
to observe the effect of low temperature, a general metabolic inhibitor. The fluorescence of cells
incubated with 6C loaded liposomes in the absence of any inhibitor was considered as 100%, while
the fluorescence after incubation in the presence of inhibitors was expressed as a relative percentage
compared to the cells without inhibitor. As shown in Figure 7, a significant reduction (about 80%) in
hCMEC/D3 cell uptake efficiency was observed at 4  C for all two formulations as compared with that
at physiological temperature, suggesting that their uptake relied on an energy-dependent pathway
and it was mediated by endocytosis [44].
To elucidate the endocytic uptake mechanisms, the experiments were also carried out in the
presence of endocytic inhibitors, such as chlorpromazine, a clathrin blocker, and indomethacin, a
caveolin-dependent endocytosis inhibitor.
Liposomes could be internalized into cells by different mechanisms, according to the type of cell,
composition, surface charge, and size of the liposome [45–47]. In our study, the cellular association of
the liposomes was significantly influenced by indomethacin, with a reduction in cellular association of
about 44% and 63% for LPs-6C and CLPs-6C, respectively (Figure 7). Caveolae-mediated endocytosis
is involved in the uptake of liposomes. However, it did not completely inhibit active uptake of the
nanoparticles when compared with the results at 4  C, confirming that cellular uptake of liposomes
involved more that on an energy-dependent pathway. In fact, as evidenced in the Figure 7, an uptake
reduction of 15% for LPs-6C and 20% for CLPs-6C was observed in the presence of chlorpromazine,
even if less pronounced than with indomethacin. This indicates that clathrin-mediated endocytosis is
also a mechanism involved in the uptake.
Therefore, the preferential mechanism of the liposomes uptake by hCMEC/D3 cells was found to
be caveolae-mediated endocytosis, with a greater effect of inhibitors in the case of CLPs-6C.
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Figure 7. Effect of the temperature (4  C) and different inhibitors on hCMEC/D3 cell internalization
pathways of LPs-6C and CLPs-6C after 2 h incubation at 37  C. (Data represent the mean ± standard
deviation (n = 3). Bars represent the mean ± SD of at least 6 experiments ** p < 0.01 vs. corresponding
liposome at 37  C; # p < 0.05 CLPs-6C vs. LPs-6C. (ANOVA + Tukey’s test).
4. Conclusions
Based on the obtained results in terms of size, homogeneity, ⇣-potential and EE%, both optimized
liposomal formulations of AG are suitable for parenteral administration. The systems showed excellent
chemical and physical stability during a month of storage as suspensions or freeze-dried products.
The optimized liposomes enhanced solubility and cellular permeability of AG, as demonstrated by
in vitro tests with PAMPA and hCMEC/D3 cells. Both carriers increase the permeation of AG into
the cell without alterations in cell viability and monolayer integrity. The presence of positive charge
elevated the cellular internalization of liposomes. Uptake experiments suggest an energy-dependent
pathway as a possible transport mechanism across the hCMEC/D3monolayer, with caveolae-mediated
endocytosis, in particular, being the main mechanism.
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